RUBY-II: Efficacy and Safety of a Ribavirin-free Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease and HCV Genotypes 1a or 4 Infection
Journal article published in 2016 by
Edward J. Gane,
Ricard Sola,
Eric Cohen,
Stuart K. Roberts,
Jacob George,
Richard Skoien,
Stephen Riordan,
Niloufar Mobashery,
Manal Abunimeh,
Daniel E. Cohen,
Kosh Agarwal 
